Why it was recalled
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Product description
fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2080-2
Lot numbers, UPCs & expiration codes
Lot: 17-270811, Exp. 7/19/2023; 17-270954, 17-270983, Exp. 7/23/2023; 17-271231, Exp. 7/26/2023; 17-271690, Exp. 8/2/2023; 17-272204, Exp. 8/13/2023; 17-272684, Exp. 8/20/2023; 17-272992, Exp. 8/24/2023; 17-273053, Exp. 8/28/2023; 17-273436, Exp. 9/3/2023.
Where it was sold
Nationwide in the USA
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-1067-2023
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- Jul 17, 2023
- FDA report date
- Aug 9, 2023
- Quantity
- 1,486 syringes
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Central Admixture Pharmacy Services Inc
Original FDA data
Every field from FDA enforcement report D-1067-2023, exactly as published.
Show all FDA fields
- City
- San Diego
- State
- CA
- Status
- Terminated
- Country
- United States
- Event ID
- 92752
- Address
- 7935 Dunbrook Rd Ste C
- Code information
- Lot: 17-270811, Exp. 7/19/2023; 17-270954, 17-270983, Exp. 7/23/2023; 17-271231, Exp. 7/26/2023; 17-271690, Exp. 8/2/2023; 17-272204, Exp. 8/13/2023; 17-272684, Exp. 8/20/2023; 17-272992, Exp. 8/24/2023; 17-273053, Exp. 8/28/2023; 17-273436, Exp. 9/3/2023.
- Postal code
- 92126-6322
- Report date
- Aug 9, 2023
- Product type
- Drugs
- Recall number
- D-1067-2023
- Classification
- Class II
- Recalling firm
- Central Admixture Pharmacy Services Inc
- Product quantity
- 1,486 syringes
- Termination date
- Mar 21, 2025
- Reason for recall
- Lack of assurance of sterility: Lack of validation data for sanitization cycles
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2080-2
- Distribution pattern
- Nationwide in the USA
- Recall initiation date
- Jul 17, 2023
- Initial firm notification
- Letter
- Center classification date
- Aug 3, 2023